meRfi®-GM
Palbociclib Plus Fulvestrant Maintains Long-Term Overall Survival Benefit in HR+:HER2– Advanced Breast Cancer
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Contents
With more than 6 years of follow-up in the phase III PALOMA-3 trial, the addition of palbociclib to fulvestrant maintained a signi!cant survival bene!t compared with fulvestrant alone in patients with HR-positive, HER2-negative advanced breast cancer that progressed on prior endocrine therapy.…